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Abstract
Purpose—An increasing number of reports have implicated bisphosphonates as contributing to
osteonecrosis of the jaw. The goal of this study was to evaluate mandible necrosis in beagle dogs
treated for three years of daily treatment with oral alendronate (ALN).
Materials and Methods—Skeletally-mature female beagles were treated daily for three years with
oral doses of vehicle or ALN (0.20 or 1.0 mg/kg/day). These doses approximate, on a mg/kg basis,
those used for post-menopausal osteoporosis and Paget’s disease, respectively. At necropsy the
2nd molar region of the mandible was excised, stained en bloc with basic fuchsin, and assessed for
matrix necrosis and intracortical bone turnover rate using histology. Matrix necrosis was defined as
a region > 500um2 that was void of basic fuchsin stain, assessed using both brightfield and confocal
microscopy.
Results—No animals developed exposed bone lesions in the oral cavity during the 3-year study.
Matrix necrosis was observed in 25% of ALN0.2 animals and 33% of ALN1.0 animals while being
noticeably absent from all vehicle animals (p < 0.05 pooled ALN doses vs VEH). These necrotic
regions occurred predominately in the alveolar bone and were clearly void of patent canaliculi.
Intracortical bone turnover rate of the alveolar mandible bone region was significantly lower (−75%,
p < 0.05) in ALN-treated animals compared to VEH.
Conclusions—Three-years of daily oral bisphosphonate treatment significantly reduces bone
turnover and increase the incidence of matrix necrosis within the mandible of dogs.
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Introduction
Osteonecrosis (literally, “dead bone”) occurs when localized populations of osteocytes die 1–
4. Localized osteonecrosis is a normal physiological process that occurs throughout the
skeleton 1 and increases in prevalence with age 2, 3. The progression of localized osteonecrosis,
from the death of a few osteocytes to a more wide-spread region of matrix necrosis, is a slow
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process 1. This progression is normally controlled through remodeling, which removes necrotic
bone matrix, thereby limiting the negative consequences of necrosis 1. In some cases, such as
occurs with osteonecrosis of the jaw (ONJ), the process of osteonecrosis becomes pathological
5–7.
Since the first literature reports linking ONJ to bisphosphonate treatment 6, 8, the public health
ramifications have quickly consumed the scientific 5, 9–12 and public communities 13. Despite
all this attention, very little is known about the relationship between bisphosphonates and ONJ
12. The overwhelming majority of documented ONJ cases have been in patients administered
high doses of intravenous bisphosphonates for treatment/prevention of cancer-related
malignancies 14–17. A smaller number of ONJ cases have been reported in patients receiving
oral bisphosphonates for treatment of post-menopausal osteoporosis 9, 11, 17. It has been
proposed that as ONJ becomes more universally defined, the incidence rate with oral
bisphosphonates may increase 18. However, even with a lower incidence rate compared to
cancer patients treated with intravenous bisphosphonates, the wide-spread use of
bisphosphonates for osteoporosis makes ONJ a significant public health issue that warrants
investigation.
Bisphosphonates reduce fracture risk and the development of skeletal metastases by
suppressing bone turnover. Turnover suppression increases the mean tissue age because
regions of older bone are remodeled less frequently. Since matrix necrosis is related to mean
tissue age 2, 3, it follows that a reduction in turnover would result in an increase in necrotic
bone matrix. The mandible, especially the alveolar bone region, has a high basal turnover rate
19, 20 and therefore may be particularly susceptible to an accumulation of necrotic bone matrix
with bisphosphonate treatment.
The goal of this study was to evaluate osteonecrosis in the mandible of dogs treated for 3 years
with clinically-relevant doses of oral alendronate. We hypothesized that tissue necrosis would




All experimental procedures were approved by the Indiana University School of Medicine
Institutional Animal Care and Use Committee prior to the start of the study. Thirty-six
skeletally mature female beagles (1–2 years old) were purchased from LBL (Reelsville, IN).
Upon arrival, lateral X-rays of all dogs were obtained to confirm skeletal maturity (closed
proximal tibia and lumbar vertebral growth plates). Animals were housed two per cage in
environmentally controlled rooms at Indiana University School of Medicine’s AALAC
accredited facility. Following two weeks of acclimatization, animals were assigned to one of
three treatment groups (n=12/treatment) by matching body weights. All dogs were treated for
3 years with oral doses of saline vehicle (VEH, 1 ml/kg/day) or alendronate (ALN 0.2 mg/kg/
day or 1.0 mg/kg/day). The ALN 0.2 dose corresponds (on a mg/kg basis) to the dose used for
the treatment of post-menopausal osteoporosis. The ALN 1.0 dose approximates, although is
slightly higher than, the dose for treatment of Paget’s disease. Alendronate was dissolved in
saline and administered to the dogs orally with a syringe each morning after an overnight fast
and at least 2 hours prior to feeding. In order to measure bone formation rate, animals were
administered intravenous fluorochrome label (calcein, 0.20 mL/kg) using a 2-12-2-5 labeling
schedule (2 days of injection, 12 day ‘off’ period, 2 days of injections, 5 day ‘off’ period,
necropsy). Following three years of treatment, animals were euthanized by intravenous
administration of sodium pentobarbital (0.22 mg/kg Beuthanasia-D Special). The left half of
each mandible was wrapped in saline soaked gauze and frozen at −20°C until analysis.
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Mandibles were thawed to room temperature and a portion encompassing the 2nd molar was
isolated (by making two parallel buccal-lingual cuts) using a band saw with a diamond coated
blade while under constant irrigation. Tissue segments were processed by bulk staining en bloc
in basic fuchsin 21 with slight modifications. Basic fuchsin stains cells and empty spaces within
the bone matrix (lacunae, canaliculi, Haversian canals, and microcracks) (Figure 1) but is
absent in necrotic matrix due to the lack of patent canalicular networks 1, 22. Using 1% basic
fuchsin dissolved in increasing concentrations of ethanol, specimens were stained according
to the following schedule: 48 hours 80% (with one change to fresh 80% solution after 24 hours),
48 hours in 95% (with one change to fresh 95% solution after 24 hours), 48 hours in 100%
(with one change to fresh 100% solution after 24 hours). Bones were placed under vacuum (20
in Hg) for all stages. This staining protocol differs from that of microdamage staining in the
duration of stain, with microdamage specimens stained 4 hours per step 23 and these specimens
stained 24 hours per step. This ‘over staining’ allows a clearer assessment of necrotic regions.
Following staining, bones were embedded undecalcified as previously described 23. Two
coronal plane histological sections (100–200 µm thick) were cut using a diamond wire saw
(Histosaw, Delaware Diamond Knives).
Brightfield histological measurements were made using a semiautomatic analysis system
(Bioquant OSTEO 7.20.10, Bioquant Image Analysis Co.) attached to a microscope (Nikon
Optiphot 2 microscope, Nikon). Under bright-field, regions of bone void of basic fuchsin stain
>500 µm2 were considered necrotic. This was chosen as it exceeds the average size of two
adjacent osteons or interstitial regions 24. Limiting areas defined as necrotic to a larger area
such as this also reduces inter-individual variability among animals in the analyses. For all
animals, two complete cross-sections of the mandible (Figure 1) were assessed for regions of
necrosis. Histological evaluation was conducted, blinded to treatment, by one investigator. All
animals were classified as yes/no for matrix necrosis and the mean two-dimensional size of
necrotic regions was measured. Necrotic regions were classified as being in the alveolar bone
(above the most distally observed portion of the tooth roo t19), or non-alveolar (the remainder
of the tissue).
Regions identified as being void of stain using brightfield microscopy were also examined
using confocal microscopy (Bio-Rad MRC1024 Laser Scanning Confocal Microscope).
Necrotic regions were imaged (2–4 separate fields of view for each necrotic zone) using a 568-
nm wavelength excitation and a 605DF32 emission filter, and a 40x water dipping objective
25.
Bone turnover rate
Intracortical bone formation rate was measured using dynamic histomorphometry. One of the
two histological sections assessed for matrix necrosis was used for these analyses; calcein
labeling could be clearly observed despite heavy basic fuchsin staining. For all measures,
alveolar bone was assessed separately from non-alveolar bone, with the two regions pooled
together to get values for the total mandible. Using UV light, the bone area (B.Ar), number of
labeled osteons (L.Os.#), the total length of osteonal labeled surface (LS), and the mean inter-
label distance (Ir.L.Dis) were measured at 10x magnification. Mineral apposition rate (MAR,
um/day) was calculated as Ir.L.Dis / 12, where 12 is the number of days between labels.
Intracortical bone formation rate (%/year) was calculated as (MAR ×(LS/2) / B.Ar × 100) ×
365. All measures and calculations were in accordance with ASBMR recommended standards
26.
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Due to the small sample size, the incidence of animals having matrix necrosis and the size of
necrotic areas were compared using one-tailed Fisher’s exact test and Mann-Whitney tests,
respectively. Dynamic bone formation parameters were compared among the vehicle and the
two alendronate doses using one-way analysis of variance (ANOVA) with Fishers protected
least significant difference post-hoc tests. As none of the variables of interest were significantly
different between the two doses of alendronate, additional comparisons were performed
between vehicle and pooled alendronate doses. For all analyses, significance was determined
using the criteria of p < 0.05. Data are presented as mean ± standard errors.
Results
There was no evidence of exposed bone in the oral cavity of any of the dogs during the 3 year
study.
Using histology, regions of matrix necrosis were observed in the mandible of three of twelve
animals (25%) treated with ALN0.2, and four of twelve animals (33%) treated with ALN1.0
(Table 1). This represents a significantly higher incidence rate in alendronate-treated animals
(7 of 24; 29%) compared to vehicle-treated animals (p < 0.05), in which no regions of matrix
necrosis were observed in any of the twelve animals. There was no difference in the incidence
rate of necrosis between the two doses of alendronate.
Necrotic regions were defined by the absence of basic fuchsin stain (Figure 2). In all cases,
necrotic regions could be observed in both of the tissue sections from a particular animal. The
majority of necrotic regions were in the alveolar regions of the mandible although two animals
(both in the ALN1.0 group) had necrotic regions in the base of the mandible bone (Table 1).
Two animals treated with ALN0.2, and one animal treated with ALN1.0 had two separate
regions of necrosis within the same tissue section. The average cross-sectional area of necrotic
tissue among all ALN-treated animals was 1.47 ± 0.21 mm2, which represents approximately
2% of the bone tissue area. This size of necrotic areas did not differ between the two doses of
ALN (Table 1).
When viewed using confocal microscopy, regions classified as necrotic using brightfield
microscopy were absent of stained osteocyte lacunae and canalicular networks (Figure 2). The
vasculature within these necrotic regions appeared sufficiently stained, suggesting the necrotic
tissue is not avascular and that the absence of matrix staining was due to the inability of the
stain to move from the vessel into the matrix because of disrupted canalicular networks. Bone
regions showing clear stain uptake using brightfield microscopy displayed clearly stained
osteocyte lacunae, canalicular networks, and blood vessels, and therefore were considered
viable bone (Figure 2). No regions considered to be viable with brightfield microscopy were
found to have compromised staining patters when viewed using confocal microscopy.
Intracortical bone formation rate of the overall mandible cross-section was significantly lower
than vehicle with ALN0.2 (−58%), ALN1.0 (−84%), or when doses were pooled (−71%)
(Figure 3). This was mainly due to suppression of turnover in the alveolar bone region, which
among all animals was 84% greater than the turnover rate in non-alveolar bone. Alveolar bone
formation was significantly lower than vehicle for ALN1.0 (−84%) and the pooled ALN doses
(−75%) (Figure 3). There was no significant difference among groups in non-alveolar bone
formation rate. Lower bone formation rate in ALN-treated animals was the result of both fewer
labeled osteons and reduced mineral apposition rate (Table 2). There was no significant
difference between the two doses of ALN for any of the dynamic histomorphometry variables.
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The existence of focal necrotic regions within the bone matrix is a normal component of the
skeleton’s lifecycle, occurring when the bone matrix outlives its’ resident osteocytes 1–4. There
is minimal consequence of focal internal matrix necrosis and assuming adequate levels of bone
turnover it is likely removed in an efficient manner. Reducing the rate of turnover, as with
bisphosphonate treatment, would be expected to increase the prevalence of matrix necrosis, as
those regions that normally develop would exist for a longer period of time and may become
larger in size. Our results are consistent with these theoretical expectations, showing that
animals treated with clinically-relevant doses of alendronate for 3 years have a significant
accumulation of necrotic bone within the mandible. These necrotic regions are void of patent
canaliculi but had retained their vasculature, the latter observation suggesting this is not an
‘avascular necrosis’.
While this study shows clear evidence of increased mandible matrix necrosis in animals treated
for three years with clinically relevant doses of alendronate, it does not address the mechanism
responsible for this result. One hypothesis is that matrix necrosis is a result of a reduction in
bone turnover. Assuming under normal conditions there is equilibrium between the rate of
matrix necrosis formation and its removal 1–3, the suppression of removal due to
bisphosphonate-induced turnover suppression would result in an increased level of necrosis.
Given the high basal turnover rate of the mandible compared to other skeletal sites 19, 20, it
would be expected that relatively little matrix necrosis would normally exist at this site and
that any change in turnover rate would result in an accumulation of necrosis. Our data are
consistent with this hypothesis as the majority of necrotic regions were localized to the alveolar
bone of the mandible; a location which we show has over 6x higher turnover compared to the
remainder of the mandible. However, two necrotic areas were observed in the mandible base,
a site with relatively low turnover suggesting there may be a component of necrosis
accumulation that is independent of turnover suppression.
An alternative hypothesis is that bisphosphonates directly affect osteocyte viability, effectively
decreasing their lifespan and increasing the rate of necrotic matrix formation. Evidence from
osteocyte culture studies argue against this hypothesis, as concentrations of bisphosphonates
estimated to exist in vivo were found to reduce osteocyte apoptosis both in vitro 27 and in vivo
28. At higher concentrations, bisphosphonates have been shown to have direct cytotoxic effects
on other cells, including fibroblasts 29 and endothelial cells 30. As bisphosphonates accumulate
in the skeleton in a dose-dependent manner 31, 32 it is possible that with prolonged exposure
the local concentrations of drug reach very high levels, perhaps exceeding those studied by
Plotkin et al 27. Such concentrations could have a cytotoxic effect on osteocytes. This
hypothesis, one of skeletal accumulation independent of turnover suppression, would be
consistent with our finding regions of necrosis in the base of the mandible (a site with low
turnover) only in those dogs treated with the higher dose of alendronate.
The connection between mandible matrix necrosis, as observed in the current study, and
osteonecrosis of the jaw (ONJ), defined as exposed oral lesions, remains unclear. We
hypothesize that increased levels of matrix necrosis represent an early stage of ONJ but that
additional perturbations of the oral cavity are necessary to manifest exposed oral lesions. Both
tooth extraction and periodontal disease have been implicated as having an interaction with
bisphosphonates in the manifestation of ONJ 33, 34. The most plausible link between
bisphosphonates and both dental extraction and periodontal disease is their contrasting effects
on bone turnover. In response to extraction the turnover rate is accentuated, most notably in
the alveolar bone surrounding the extraction site (up to 400%/year) 35. Increased turnover also
occurs with periodontal disease or other instances in which infection is present in the oral region
(osteomyelitis). Therefore in the presence of bisphosphonates, the normal enhancement of
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turnover in each of these instances is prevented, perhaps leading to an accumulation of non-
viable osteocytes which progresses to necrotic bone matrix, and eventually the clinical
manifestation of ONJ.
Limitations exist for studying ONJ in humans, emphasizing the need to develop an animal
model to help understand the pathophysiology of ONJ and to eventually test treatment or
prevention 12. The canine model is routinely utilized in skeletal biology and offers numerous
advantages for studying ONJ. First, the turnover rates in beagles are similar to humans with a
slightly shorter remodeling period (3 months in dog versus 4–6 months in humans) 36, 37. This
allows studies where changes in turnover may have an important physiological role to be
conduced using a condensed time-frame. Secondly, the alveolar bone of the dog mandible has
high levels of intra-cortical remodeling, similar to humans 19, 20, 35. One perceived limitation
of the canine model is that it is not a model of osteoporosis (or osteopenia) as dogs do not lose
bone when ovariectomized. However, as ONJ is not a condition that appears linked to either
estrogen deficiency or low bone mass, this is not a significant limitation to the model.
The current study has various limitations. As we did not examine the entire mandible it is not
possible to determine the true extent of necrosis in bisphosphonate-treated animals nor
eliminate the possibility vehicle-treated animals have necrotic regions. However, three
additional 1 mm tissue segments were examined in all dogs (2 sections per region). These
additional sections showed no evidence of necrosis in any of the vehicle-treated animals nor
did they show necrosis in any additional alendronate-treated dogs. Regions of necrosis were
evident in other segments of two dogs that had necrosis in the 2nd molar region. We therefore
consider the results in the 2nd molar region to be representative of the matrix necrosis in these
animals. For this study, necrotic regions were defined as those > 500 µm2, which exceeds the
average size of two adjacent osteons or interstitial regions 24. This explains the absence of
necrosis in vehicle-treated animals. Indeed, smaller regions of the bone matrix that were void
of stain could be observed in both alendronate- and vehicle-treated animals, using brightfield
microscopy. Limiting areas defined as necrotic to a larger area such as > 500 µm2 also reduces
inter-individual variability among animals in the analyses. Finally, this study provides no
conclusive evidence that these necrotic lesions are related to the clinical condition of ONJ.
In conclusion, we have shown that following three years of treatment with clinically-relevant
doses of oral alendronate, regions of bone matrix necrosis existed within the mandible of beagle
dogs. We propose the matrix necrosis observed in these animals represents an early stage of a
process that may eventually result in the clinical manifestation of osteonecrosis of the jaw.
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Basic fuchsin stained histological section through the 2nd molar region. Dotted line at the base
of the tooth root separates the alveolar (above line) and non-alveolar (below line) regions for
classifying locations of necrosis and bone turnover rate.
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Matrix necrosis in the mandible of dogs treated for 3 years with alendronate. The second molar
region was stained en bloc with basic fuchsin with regions of matrix necrosis defined as those
regions void of stain uptake. Necrotic bone matrix can be observed using brightfield
microscopy (A, D, E). Due to its fluorescent properties, stained regions can be visualized using
confocal microscopy, revealing patent canalicular networks (B,G). Conversely, necrotic
regions which are void of stain can are without patent canalicular networks (C, F, H).
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Bisphosphonates significantly reduce intracortical bone formation rate in the mandible. There
was a significant reduction in the overall bone formation rate of the mandible with both doses
of alendronate (ALN) or when the two doses of ALN were pooled. There was no significant
difference between the two doses of ALN. The greatest suppression of turnover was noted in
the alveolar portion of the mandible with no significant effect of ALN treatment on turnover
suppression in the non-alveolar portion. Across all groups turnover was 84% lower in the non-
alveolar region compared to the alveolar region. * p < 0.05 versus VEH.
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Table 1








Animals 12 12 12 24
Animals with
necrosis, #
0 3 4 7a
Necrosis area,
mm2





-- Alveolar Alveolar and non-alveolar Alveolar and non-alveolar
a
p < 0.05 versus vehicle.
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Table 2








N 12 12 12 24
Alveolar bone
Bone area, mm2 15.6 ± 1.7 13.3 ± 1.1 17.4 ± 2.3 15.2 ± 1.3
Labeled osteons,
#/mm2
0.52 ± 0.18 0.25 ± 0.12 0.13 ± 0.10 0.20 ± 0.08
MAR, um/day 1.37 ± 0.25 0.56 ± 0.25 a 0.39 ± 0.28 a 0.37 ± 0.15 a
Non-alveolar
bone
Bone area, mm2 43.1 ± 2.7 48.0 ± 3.1 50.1 ± 3.3 49.0 ± 2.2
Labeled osteons,
#/mm2
0.062 ± 0.02 0.038 ± 0.01 0.004 ± 0.002 a 0.02 ± 0.01 a
MAR, um/day 0.80 ± 0.25 0.72 ± 0.23 0.21 ± 0.14 0.50 ± 0.15
Overall
mandible
Bone area, mm2 58.6 ± 3.5 61.3 ± 3.2 67.4 ± 2.9 64.2 ± 2.2
Labeled osteons,
#/mm2
0.18 ± 0.04 0.09 ± 0.03 a 0.03 ± 0.02 a 0.06 ± 0.02 a
Data (mean ± SE) represent one tissue section per animal.
a
p < 0.05 versus vehicle.
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